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The Impact of Donor and Recipient Renal Dysfunction on Cardiac Allograft
Survival: Insights into Reno-Cardiac Interactions. Olga Laur, Meredith A. Brisco, and
Jeffrey M. Testani. Section of Cardiology, Department of Internal Medicine, Yale University,
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Background: Renal dysfunction (RD) is a potent risk factor for death in patients with
cardiovascular disease. This relationship may be causal since experimentally induced RD
produces findings such as myocardial necrosis and apoptosis in animals. Cardiac transplantation
provides an opportunity to investigate this hypothesis in humans; if direct myocardial damage is
principally responsible for the substantial risk associated with RD, this risk should be transferable
from a donor with RD to the recipient via the allograft.
Methods: Cardiac transplantations from the UNOS registry were studied (n=23,056). RD was
defined as an estimated glomerular filtration rate < 60 ml/min/1.73m.2
Results: RD was present in 17.9% of donors and 39.4% of recipients. Donor characteristics that
could theoretically result in myocardial damage such as longer ischemic time, older age, diabetes,
hypertension, and cigarette use were associated with increased graft failure (p≤0.007 for all).
However, donor RD was not associated with graft failure (age-adjusted HR=1.00, 95% CI 0.941.07, p=0.92). Moreover, in recipients with RD the highest risk for graft failure occurred
immediately post-transplant (0-30 day HR=1.8, 95% CI 1.54-2.02, p<0.001) with subsequent
attenuation of the risk over time (30-365 day HR=0.92, 95% CI 0.77-1.09, p=0.33).
Conclusions: The risk associated with RD does not appear to be transferrable from donor to
recipient via the cardiac allograft and the risk associated with recipient RD is greatest
immediately following transplant. These observations suggest that the non-myocardial aspects of
cardio-renal dysfunction are of particular importance in the risk associated with RD.
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Introduction:
Renal dysfunction (RD) is common in patients with cardiovascular disease and is
strongly associated with increased morbidity and mortality.1-7 Notably, this association
persists after extensive adjustment for potential confounders, such as diabetes or
hypertension, raising the possibility of a causal relationship. One potential mechanism by
which RD may directly worsen outcomes is via direct myocardial damage.8-12 Support for
this possibility is derived from animal studies where experimentally induced RD results
in pathology such as necrosis, apoptosis, fibrosis, arteriolar thickening, decreased
capillary density, and contractile dysfunction.13-19 Remarkably, some of these findings
have also been reported following only brief exposures to RD in the setting of
experimental acute kidney injury (AKI).20
Whether RD can cause direct myocardial damage in humans with enough severity
to influence outcomes is unknown and represents a difficult hypothesis to test. In addition
to potential direct myocardial effects, the epidemiologic signal for adverse outcomes
associated with RD could also be driven by non-myocardial/peripheral factors intrinsic to
the RD milieu, which are difficult to measure. These factors could take the shape of
systemic myocardial depressant factors (i.e., “uremic toxins”) effects on the vasculature
and other organs, in addition to unmeasured confounding factors (i.e., underutilization of
beneficial therapies due to the RD or unmeasured disease severity).
Cardiac transplantation provides an opportunity to begin to investigate the
importance of myocardial vs. peripheral effects of RD since the heart is being
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transplanted into and out of the RD environment. When a heart is removed from a donor
with RD, the peripheral RD environment will remain with the donor. However, any RDinduced myocardial damage will travel to the recipient with the graft. Thus, if significant
myocardial damage occurs with RD we would expect this injury to travel with the heart
and result in reduced post-transplant graft survival in recipients (Figure 1).21 In essence,
this finding would be similar to the concept that the myocardial damage induced by
factors such a longer graft ischemic time or from advanced donor age results in worsened
post-transplant outcomes (despite the rigorous graft selection process that seeks to avoid
these exposures).

Figure 1. Hypothetical effect of donor RD on graft survival in recipients under
assumption that donor RD causes direct myocardial damage

Similarly, transplanting a healthy heart into a recipient with RD would be
expected to result in a progressive increase in risk over time after enough myocardial
damage accumulates from the RD to begin to impact clinical outcomes(Figure 2).
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Figure 2. Hypothetical effect of recipient RD on graft survival in recipients under
assumption that RD causes myocardial damage which accumulates in a timedependent manner

However, if the risk associated with RD is primarily driven by the host’s
peripheral RD environment (i.e., systemic myocardial depressant factors), we would
expect to see limited risk from donor RD but a significant up-front risk associated with
transplant of a healthy donor heart into the environment of recipient RD. That is, we
would expect the rate of graft failure to be accelerated post-transplantation in a group of
recipients with RD followed by stabilization in the rate of graft failure between the two
groups following a critical period of time (Figure 3).
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Figure 2.
Hypothetical effect of recipient RD graft survival in recipients under assumption
that RD is a marker of patient disease severity rather then causes direct myocardial
damage

Study aim:
As such, the primary purpose of this analysis was to evaluate the risk associated
with donor RD on post-transplant outcomes and to determine the temporal pattern of
cardiovascular risk associated with recipient RD following transplantation of healthy
donor hearts. This was accomplished using heart transplant records from United Network
for Organ Sharing (UNOS) database, which is a national database that collects recipient
and donor heart transplant data via established questionnaires distributed to all of the
transplant centers.

Hypothesis 1: It is unlikely that renal dysfunction exerts direct damaging effect on
myocardium and thus transplantation of donor hearts with and without history of RD will
yield similar recipient graft outcomes.
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Hypothesis 2: It is unlikely that renal dysfunction exerts direct damaging effect on
myocardium and thus transplantation of donor hearts with and without history of
proteinuria will yield similar recipient graft outcomes.

Hypothesis 3: It is unlikely that renal dysfunction exerts direct damaging effect on
myocardium and thus transplantation of donor heart into the recipient environment of RD
will not result in a time-dependent acceleration in graft failure compared to donor graft
transplantation into recipients with no history of RD. Instead, we would expect to see a
significant up-front risk associated with transplant of a healthy donor heart into the
environment of recipient RD.

Methods:
Patient Population:
Cardiac transplant donor and recipient data were obtained for adult cardiac
transplants between January 2000 and March 2013 (N=28,513) from the United Network
for Organ Sharing (UNOS) database. Patients receiving either heart-lung or heart-kidney
transplants and those with missing data on donor and recipient serum creatinine, donor
race, or graft outcomes were excluded. For patients who underwent re-transplantation
(n=1,620), only data on the first transplant was retained. Overall, 23,056 patients met the
inclusion criteria (Figure 4).
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Figure 4. Consort diagram

Estimated glomerular filtration rate (eGFR) was calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.22 Terminal creatinine
was used for donor eGFR calculation; serum creatinine at the time of transplant was used
for recipient eGFR calculation. Subsequent recipient renal function was evaluated in a
subset of patients with follow-up data available (n = 8,802). RD was defined as an eGFR
< 60 ml/min/1.73m2.23, 24 Both donor and recipient groups were additionally stratified
into National Kidney Foundation (NKF) stages of CKD severity (GFR ≥ 90
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ml/min/1.73m2, GFR 60-89 ml/min/1.73m2, GFR 30-59 ml/min/1.73m2, and GFR <30
ml/min/1.73m2 where NKF stages 4 and 5 were combined).23 Several donor or recipient
dichotomous characteristics had a high degree of missingness (i.e., recipient cigarette use
missing >30%) and there was prognostic information associated with the missing state of
these variables. To ensure that the multivariable models captured as much risk as possible,
these variables were coded using three levels (i.e., cigarette use yes, no, missing).

Statistical Analysis:
The primary focus of this analysis was (1) the association between donor RD and
cardiac graft failure and (2) the time-dependent nature of the association between
recipient RD and cardiac graft failure. A secondary analysis focused on the relationship
between donor proteinuria and cardiac allograft failure. The primary endpoint of these
analyses was recipient graft failure which was defined as retransplantation or recipient
death during the study period. Values reported are mean ± SD or median (quartile 1 –
quartile 4) for continuous variables, or percentile for categorical variables. Independent
Student’s t test was used to compare continuous variables. The Pearson chi-square test
was used to evaluate associations between categorical variables. Correlation coefficients
reported are Spearman’s rho.
Cox proportional hazards models were used to evaluate time-to-event
associations between both donor RD and recipient RD with graft failure. Patients were
censored if lost to follow-up or alive at the conclusion of the data collection period

8

(March 2013). Given the strong influence of donor age on graft survival and the strong
influence of age on calculated eGFR, all models evaluating the association between
eGFR and graft failure were adjusted for age unless otherwise specified.21, 25 Covariates
for multivariable models included all donor, recipient and graft-related factors with a
univariate association with graft failure at p<0.2 or a theoretical basis for confounding
(donor and graft covariates = gender, diabetes, hypertension, cigarette use, cause of death,
CMV status, infection, inotrope use, ischemic time, and donor ejection fraction; recipient
covariates = eGFR, age, gender, race, BMI, diabetes, hypertension, cerebrovascular
disease, ischemic cardiomyopathy, cigarette use, UNOS status at listing, mechanical
ventilation, inotrope, intra-aortic balloon pump, mechanical circulatory support use,
recipient CMV status, and donor-recipient mismatch in gender). Kaplan-Meier survival
curves were plotted for four groups of donor and recipient eGFR (eGFR ≥ 90, eGFR 6089, eGFR 30-59, and eGFR <30 ml/min/1.73m2). The x-axis was terminated when the
number at risk was <10% and statistical significance was determined using the log-rank
test. When evaluating the association between recipient eGFR and graft failure, our
primary focus was how the effect of RD on graft outcomes changed over time. As such,
we performed an extended adjusted cox model utilizing two Heaviside functions to
examine the magnitude of the effect of RD on graft outcomes in the first 30 days and
from 30 days to 1 year. For all analyses, a p-value of <0.05 was considered statistically
significant. Statistical analyses were performed using SPSS Version 19 (IBM SPSS
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Statistics, IBM Corporation, Armonk, New York) and Stata 13.0 (Statacorp, College
Station Texas).

Coding analysis:
All coding necessary for UNOS database cleaning, donor and recipient eGFR estimation,
univariate and multivariate cox regression analysis for donor RD, donor proteinuria, and
recipient RD over the total length of the post-transplant follow-up was performed by me
using SPSS software (see below). Adjusted extended cox model utilizing two Heaviside
function was performed by Dr. Meredith Brisco via Stata software.

Coding for estimation of eGFR in donor and recipient:
**CKD EPI equation race 1 = African American ; 0 = non African American**
Compute EPIsexMultiplier=$sysmis.
if Race_don eq 1 and gender_don eq "F" EPIsexMultiplier=166.
if Race_don eq 1 and gender_don eq "M" EPIsexMultiplier=163.
if Race_don eq 0 and gender_don eq "F" EPIsexMultiplier=144.
if Race_don eq 0 and gender_don eq "M" EPIsexMultiplier=141.
EXECUTE.

Compute EPIexponent=$sysmis.
if gender_don eq "F" and creat_don LE 0.7 EPIexponent=-0.329.
if gender_don eq "F" and creat_don gt 0.7 EPIexponent=-1.209.
if gender_don eq "M" and creat_don LE 0.9 EPIexponent=-0.411.
if gender_don eq "M" and Creat_don gt 0.9 EPIexponent=-1.209.
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EXECUTE.

compute Episex=$sysmis.
if gender_don="F" Episex= 0.7.
if gender_don="M" Episex=0.9.
EXECUTE.

compute CKD_EPI_donor=$sysmis.
compute CKD_EPI_donor=
EPIsexMultiplier*((creat_don/EPIsex)**EPIexponent)*(0.993**age_don).
EXECUTE.

Coding for stratifying donor and recipient groups into stages:
COMPUTE CKD_EPI_donorstage=$sysmis.
if CKD_EPI_donor ge 90 CKD_EPI_donorstage= 0.
if CKD_EPI_donor ge 60 and CKD_EPI_donor lt 90 CKD_EPI_donorstage=1.
if CKD_EPI_donor ge 30 and CKD_EPI_donor lt 60 CKD_EPI_donorstage=2.
if CKD_EPI_donor ge 0 and CKD_EPI_donor lt 30 CKD_EPI_donorstage=3.
EXECUTE.

COMPUTE CKD_EPI_recipstage=$sysmis.
if CKD_EPI_recip ge 90 CKD_EPI_recipstage= 0.
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if CKD_EPI_recip ge 60 and CKD_EPI_recip lt 90 CKD_EPI_recipstage=1.
if CKD_EPI_recip ge 30 and CKD_EPI_recip lt 60 CKD_EPI_recipstage=2.
if CKD_EPI_recip ge 0 and CKD_EPI_recip lt 30 CKD_EPI_recipstage=3.
EXECUTE.

Coding for unadjusted donor RD cox regression model:

COXREG time
/STATUS=gfailure(1)
/METHOD=ENTER CKD_EPI60donor age_doncox10
/PRINT=CI(95)
/CRITERIA=PIN(.05) POUT(.10) ITERATE(20).

Coding for unadjusted donor proteinuria cox regression model:

COXREG time
/STATUS=gfailure(1)
/METHOD=ENTER prot_donor
/PRINT=CI(95)
/CRITERIA=PIN(.05) POUT(.10) ITERATE(20).

Coding for donor RD cox regression model adjusted with donor and recipient risk
factors:
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COXREG time
/STATUS=gfailure(1)
/CONTRAST (htn_recip1)=Indicator(1)
/CONTRAST (cig_recip1)=Indicator(1)
/CONTRAST (cmv_recip1)=Indicator(1)
/CONTRAST (allinotropes1)=Indicator(1)
/METHOD=ENTER CKD_epi60donor CKD_epirecipcox10 agecox10 gender_recip
gender_mismatch1 race_recip BMI_CALC diab_recip htn_recip1 cereb_recip
cig_recip1
ischCM vent_recip inotropes_trr iabp_trr stat_recip ischtime LV_eject cmv_recip1
mech_circ_support age_doncox10 gender_donor diab_donor htn_donor cig_donor
cod_anoxia_donor cmv_donor donor_infection allinotropes1
/PRINT=CI(95)
/PRINT=CI(95)
/CRITERIA=PIN(.05) POUT(.20) ITERATE(20).

Coding for donor proteinuria cox regression model adjusted with donor and recipient risk
factors:
COXREG time
/STATUS=gfailure(1)
/CONTRAST (htn_recip1)=Indicator(1)
/CONTRAST (cig_recip1)=Indicator(1)
/CONTRAST (cmv_recip1)=Indicator(1)
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/CONTRAST (allinotropes1)=Indicator(1)
/METHOD=ENTER prot_donor CKD_epirecipcox10 agecox10 gender_recip
gender_mismatch1 race_recip BMI_CALC diab_recip htn_recip1 cereb_recip
cig_recip1
ischCM vent_recip inotropes_trr iabp_trr stat_recip ischtime LV_eject cmv_recip1
mech_circ_support age_doncox10 gender_donor diab_donor htn_donor cig_donor
cod_anoxia_donor cmv_donor donor_infection allinotropes1
/PRINT=CI(95)
/PRINT=CI(95)
/CRITERIA=PIN(.05) POUT(.20) ITERATE(20).

Coding for recipient RD unadjusted Cox regression model:

COXREG time
/STATUS=gfailure(1)
/METHOD=ENTER CKD_EPI60recip agecox10
/PRINT=CI(95)
/CRITERIA=PIN(.05) POUT(.10) ITERATE(20).

Coding for recipient RD cox regression model adjusted with donor and recipient risk
factors:
COXREG time
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/STATUS=gfailure(1)
/CONTRAST (htn_recip1)=Indicator(1)
/CONTRAST (cig_recip1)=Indicator(1)
/CONTRAST (cmv_recip1)=Indicator(1)
/CONTRAST (allinotropes1)=Indicator(1)
/METHOD=ENTER CKD_epi60recip CKD_epi_donorcox10 agecox10 gender_recip
gender_mismatch1 race_recip BMI_CALC diab_recip htn_recip1 cereb_recip
cig_recip1
ischCM vent_recip inotropes_trr iabp_trr stat_recip ischtime LV_eject cmv_recip1
mech_circ_support age_doncox10 gender_donor diab_donor htn_donor cig_donor
cod_anoxia_donor cmv_donor donor_infection allinotropes1
/PRINT=CI(95)
/PRINT=CI(95)
/CRITERIA=PIN(.05) POUT(.20) ITERATE(20).

Coding provided by Dr. Meredith Brisco:
**FINAL MODEL evaluating Hazard ratio associated with recipient RD at 1 month posttransplantation and following 1 month post transplantation.

stsplit rd, at(30)
gen rd1mo=CKD_EPI60recip*(rd==30)

xi: stcox CKD_EPI60recip rd1mo age_doncox10
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xi: stcox CKD_EPI60recip rd1mo age_doncox10 CKD_EPI_donorcox10 agecox10
gender_recip gender_mismatch1 race_recip BMI_CALC ///
diab_recip i.htn_recip1 cereb_recip i.cig_recip1 ischCM vent_recip INOTROPES_TRR
IABP_TRR stat_recip ischtime LV_EJECT i.cmv_recip1 ///
mech_circ_support gender_donor diab_donor htn_donor cig_donor cod_anoxia_donor
cmv_donor donor_infection i.allinotropes1

Results:
Donor Characteristics:
In total, 23,056 patients met the inclusion criteria. Baseline donor characteristics
stratified by presence of donor RD are presented in Table 1.
Table 1. Baseline donor characteristics stratified by presence or absence of donor
renal dysfunction
Overall

P-value

Donor RD Present

Cohort
(n = 23,056)

No (n = 18,919)

31.6 ± 12.2

30.9 ± 12.1

34.6 ± 11.9

<0.001

Age > 50 years

8.0%

7.5%

10.3%

<0.001

Female gender

28.6%

28.3%

30.1%

0.020

White race

85.9%

86.4%

83.5%

<0.001

26.6 ± 5.6

26.3 ± 5.5

28.1 ± 5.9

<0.001

Characteristic

Yes (n = 4,137)

Demographics
Age, years

BMI
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Comorbidities
Diabetes mellitus

2.6%

2.3%

4.2%

<0.001

Hypertension

13.1%

11.2%

21.5%

<0.001

Cigarette use

22.6%

22.3%

23.8%

0.030

Alcohol use

19.5%

19.0%

22.2%

0.013

CMV positive

61.3%

61.2%

61.8%

0.460

Suspected infection

7.0%

6.9%

7.6%

0.094

Anoxia

13.3%

10.8%

25.1%

<0.001

Stroke

24.9%

24.2%

28.0%

<0.001

Head trauma

60.8%

63.9%

46.5%

<0.001

3.2 ± 1.0

3.2 ± 1.0

3.2±1.0

0.013

21.0%

20.8%

22.2%

0.050

61.6 ± 7.6

61.5 ± 7.7

61.8 ± 7.6

0.047

LVEF ≤ 45%

2.2%

2.3%

1.9%

0.100

Inotropic support

61.9%

61.6%

63.3%

0.045

15.5 ± 12.4

12.7 ± 7.8

28.0 ± 19.7

<0.001

1.3 ± 1.2

0.9 ± 0.3

2.8 ± 2.1

<0.001

92.2 ± 34.8

104.1 ± 25.0

37.7 ± 16.3

<0.001

32.6%

28.8%

50.1%

<0.001

Donor cause of death

Cardiac allograft
Ischemic time, hours
Ischemic time ≥ 4 hours
LVEF, %

Laboratory values
BUN, mg/dl
Creatinine, mg/dl
eGFR, ml/min/1.73m2
Proteinuria
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RD: renal dysfunction, BMI: body mass index, CMV: cytomegalovirus, LVEF: left
ventricular ejection fraction, BUN: blood urea nitrogen, eGFR: estimated glomerular
filtration rate.

RD was present in 17.9% of donors with a mean eGFR that was significantly depressed
at 37.7 ± 16.3 ml/min/1.73m2 and an elevated creatinine at 2.8 ± 2.1 mg/dl. Donors with
RD were older, with a substantially higher prevalence of diabetes, hypertension, and
death from anoxic cause. However, measures of cardiac allograft function such as
ejection fraction and inotrope use were generally similar between groups as was the graft
ischemic time (Table 1).

Donor RD and graft failure:
Out of 23,056 recipients, 6,852 (29.7%) experienced graft failure during a median
follow-up of 3.9 (IQR 1.1-7.0) years. Serving as a positive control, donor risk factors
that could potentially induce myocardial damage such as older donor age, hypertension,
diabetes, cigarette use, and longer ischemic time were all significantly associated with
recipient graft failure (Figure 5 and Table 2).
Table 2. Donor and recipient characteristics and their associations with graft failure
HR

95% CI

P-value

Age, per 10 year increase

1.11

1.09-1.14

<0.001

Age > 50 years

1.35

1.25-1.46

<0.001

Donor Characteristics
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Female gender

1.12

1.07-1.18

<0.001

Diabetes mellitus

1.22

1.05-1.41

0.007

Hypertension

1.13

1.06-1.22

<0.001

Cigarette use

1.18

1.11-1.24

<0.001

CMV positive

1.11

1.06-1.16

<0.001

Suspected infection (blood)

1.12

1.02-1.22

0.02

Donor inotropic support

1.07

1.01-1.13

0.02

Donor cause of death: anoxia

1.02

0.95-1.10

0.56

eGFR, per 10 ml/min/1.73m2 increase

1.00

0.99-1.01

0.96

eGFR < 90 ml/min/1.73m2

1.02

0.97-1.07

0.44

eGFR < 60 ml/min/1.73m2

1.00

0.94-1.07

0.92

eGFR < 45 ml/min/1.73m2

1.00

0.93-1.09

0.96

eGFR < 30 ml/min/1.73m2

0.92

0.83-1.03

0.14

Creatinine, per 1mg/dl increase

1.00

0.97-1.02

0.65

Creatinine > 1.5 mg/dl

1.01

0.95-1.08

0.71

Creatinine > 2.0 mg/dl

0.94

0.86-1.04

0.22

Creatinine > 2.5 mg/dl

0.99

0.89-1.10

0.78

Proteinuria

1.00

0.95-1.05

0.96

Ischemic time, hours

1.08

1.05-1.10

<0.001

Ischemic time ≥ 4 hours

1.22

1.15-1.29

<0.001

Donor renal function *

Cardiac Allograft Characteristics
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LVEF, %

1.00

1.00-1.00

0.62

LVEF ≤ 45%

1.12

0.96-1.29

0.15

Age, per 10 year increase

1.00

0.98-1.02

0.76

Female gender

1.06

1.00-1.12

0.04

Gender mismatch

1.15

1.08-1.22

<0.001

Race

1.35

1.27-1.44

<0.001

BMI

1.01

1.00-1.02

<0.001

Diabetes mellitus

1.19

1.13-1.26

<0.001

Hypertension

1.17

1.11-1.24

<0.001

Cerebrovascular disease

1.18

1.07-1.30

0.001

Cigarette use

1.09

1.02-1.17

0.01

Ischemic cardiomyopathy

1.16

1.10-1.21

<0.001

CMV positive

1.10

1.04-1.16

<0.001

Inotropic support

1.05

1.00-1.10

0.07

IABP

1.22

1.10-1.34

<0.001

Mechanical circulatory support

1.14

1.07-1.22

<0.001

UNOS status 1A

1.13

1.08-1.19

<0.001

Mechanical ventilation

1.20

1.04-1.37

0.01

Recipient eGFR, per 10

0.95

0.94-0.96

<0.001

2
ml/min/1.73m
Recipient eGFRincrease
< 90 ml/min/1.73m2

1.13

1.06-1.21

<0.001

Recipient Characteristics

Recipient renal function *
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Recipient eGFR < 60 ml/min/1.73m2

1.28

1.21-1.34

<0.001

Recipient eGFR < 45 ml/min/1.73m2

1.45

1.37-1.54

<0.001

Recipient eGFR < 30 ml/min/1.73m2

1.80

1.60-1.94

<0.001

*All donor eGFR covariates were adjusted for donor age and recipient eGFR covariates
were adjusted for recipient age. CMV: cytomegalovirus, eGFR: estimated glomerular
filtration rate, LVEF: left ventricular ejection fraction, RD: renal dysfunction, BMI: body
mass Index, IABP: intra-aortic balloon pump, UNOS: United Network of Organ Sharing.

Figure 5. Risk of graft failure from selected donor risk factors with theoretical
direct deleterious effects on the myocardium. eGFR: estimated glomerular filtration
rate. *Due to the dependence of eGFR on age, all eGFR categories were adjusted for
donor age.

However, there was no significant relationship between donor RD and graft
failure (HR=1.05 95% CI 0.98-1.12 p=0.14). Following adjustment for age, the hazard
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ratio further approached unity (HR= 1.00, 95% CI 0.94-1.07, p=0.92). A similar lack of
association between donor RD and graft failure was observed with larger reductions in
eGFR and using creatinine-based cut points to define RD (Figure 5). Further adjustment
for other donor characteristics (HR=0.99, 95% CI 0.92-1.06, p=0.76) or donor and
recipient characteristics did not alter the lack of relationship between donor RD and graft
survival (HR= 0.98, 95% CI 0.92-1.05, p=0.60, Table 3).
Table 3. Association between donor renal dysfunction and recipient graft failure
adjusted for donor and recipient risk factors
HR

95% CI

P-value

Donor Characteristics
eGFR < 60 ml/min/1.73m2
Age, per 10 year increase
Female gender
Diabetes mellitus
Hypertension
Cigarette use
CMV positive
Suspected infection (blood)
Cause of death: anoxia
Inotropic support*

0.98

0.92-1.05

0.60

1.11

1.08-1.13

<0.001

0.96

0.86-1.07

0.45

1.18

1.01-1.38

0.04

0.95

0.88-1.04

0.26

1.07

1.00-1.14

0.03

1.1

1.05-1.17

<0.001

1.10

1.00-1.22

0.06

1.07

0.99-1.17

0.10

1.04

0.97-1.1

0.26

1.07

1.04-1.10

<0.001

Cardiac Allograft Characteristics
Ischemic time, hours
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LVEF, %

1.00

1.00-1.00

0.19

0.93

0.90-0.95

<0.001

1.14

1.05-1.24

0.003

1.18

1.04-1.33

0.01

1.40

1.31-1.50

<0.001

1.00

1.00-1.01

0.34

1.14

1.07-1.21

<0.001

1.12

1.05-1.20

<0.001

1.10

0.98-1.22

0.11

1.05

0.98-1.14

0.19

1.19

1.13-1.27

<0.001

1.04

0.98-1.10

0.21

1.02

0.96-1.07

0.59

1.08

0.97-1.22

0.17

1.20

1.11-1.30

<0.001

1.11

1.05-1.18

<0.001

1.19

1.02-1.38

0.03

0.95

0.94-0.96

<0.001

Recipient Characteristics
Age (per 10 year increment)
Female gender
Gender mismatch
Black race
BMI
Diabetes mellitus
Hypertension*
Cerebrovascular disease
Cigarette use*
Ischemic cardiomyopathy
CMV positive*
Inotrope use
IABP
Mechanical circulatory support
UNOS status 1A
Mechanical ventilation
eGFR, per 10 ml/min/1.73m2 increase

*Missing data in these covariates was coded as a separate category due to its prevalence
(9% for donor inotropic support; 50% for recipient hypertension; 36% for recipient
history of cigarette use, 6% for recipient cmv positive status). The associated HR
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specifically represents the risk of graft failure in a group with one of these risk factors vs.
without. eGFR: estimated glomerular filtration rate, CMV: cytomegalovirus, LVEF: left
ventricular ejection fraction, RD: renal dysfunction, BMI: body mass Index, IABP: intraaortic balloon pump, UNOS: United Network of Organ Sharing.
A “dose-response” relationship between donor eGFR and graft failure was not
apparent as progressively worse donor CKD stages (Figure 6) and eGFR as a continuous
parameter (adjusted HR=1.00 per 10 ml/min/1.73m2, 95% CI 1.00-1.01, p=0.37) were
not associated with increased risk of graft failure.
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Figure 6. Kaplan-Meier survival plots stratified by donor eGFR categories. eGFR:
estimated glomerular filtration rate in mL/min/1.73m2.

Donor proteinuria and graft failure:
In total, 32.6% of donors (n=7,406) had proteinuria at the time of evaluation. Not
surprisingly, proteinuria was more common in donors with hypertension (37.1% vs.
31.9%, p<0.001) and in donors with diabetes (41.2% vs. 32.3%, p<0.001). Donor
proteinuria was not associated with decreased graft survival (HR=1.00, 95% CI 0.95-1.05,
p=0.96, Figure 5), and this lack of association persisted with extensive adjustment for
donor and recipient characteristics (HR=1.00, 95% CI 0.94-1.06, p=0.97, Figure 7).
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Figure 7. Kaplan-Meier survival plots stratified by donor proteinuria.

Recipient characteristics:
Baseline characteristics of recipients with and without RD are presented in Table
4.

Table 4. Baseline recipient characteristics stratified by presence or absence of
recipient renal dysfunction
Overall
Characteristic

Cohort
(n = 23,056)

Recipient RD present
No (n = 13,982)

P - value

Yes (n = 9,074)
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Demographics
Age, years

52.3 ± 12.3

49.3 ± 13.0

56.8 ± 9.7

<0.001

Female gender

24.4%

24.2%

24.7%

0.372

Gender mismatch

15.8%

16.3%

15.1%

0.017

White race

82.7%

80.9%

85.6%

<0.001

26.8 ± 4.8

26.5 ± 4.9

27.2 ± 4.6

<0.001

Diabetes mellitus

24.0%

21.0%

28.6%

<0.001

Hypertension

40.1%

38.2%

42.9%

<0.001

Peripheral vascular

3.4%

2.7%

4.5%

<0.001

disease
Cerebrovascular
disease

5.5%

5.2%

6.0%

0.011

Cigarette use

49.0%

48.1%

50.5%

0.005

Ischemic cardiomyopathy

38.4%

35.2%

43.4%

<0.001

CMV positive

62.1%

61.1%

63.6%

<0.001

transplant
Inotropes

43.0%

41.0%

45.9%

<0.001

IABP

5.3%

5.1%

5.7%

0.028

Mechanical circulatory

21.8%

24.1%

18.2%

<0.001

supportstatus 1A
UNOS

44.2%

45.6%

42.1%

<0.001

Mechanical ventilation

4.1%

4.3%

3.9%

0.093

3.2 ± 1.0

3.2 ±1.0

3.2 ±1.0

0.110

BMI
Comorbidities

Disease severity at

Cardiac allograft
Ischemic time (hours)
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Ischemic time ≥ 4 hours

21.0%

20.7%

21.5%

0.137

61.6 ± 7.6

61.7±7.6

61.4±7.7

0.008

2.2%

2.0%

2.5%

0.010

1.3 ± 0.7

1.0 ± 0.2

1.8 ± 0.8

<0.001

69.9 ± 26.5

86.2 ± 20.1

44.7 ± 10.9

<0.001

MPAP, mm/Hg

28.3 ± 10.2

27.9 ± 10.3

29.0 ± 10.0

<0.001

PCWP, mm/Hg

18.8 ± 8.8

18.5 ± 8.9

19.2 ± 8.6

<0.001

TPG, mm/Hg

9.6 ± 5.4

9.5 ± 5.5

9.8 ± 5.3

0.001

CO, L/min

4.5 ± 1.5

4.5 ±1.5

4.6 ±1.5

0.018

PVR, Wood units

2.4 ±2.0

2.4 ± 1.9

2.4 ± 2.0

0.324

LVEF
LVEF ≤ 45%
Laboratory values
Creatinine, mg/dl
eGFR, ml/min/1.73m2
Hemodynamics

RD: renal dysfunction, BMI: body mass Index, CMV: cytomegalovirus, IABP: intraaortic
balloon pump, UNOS: United Network of Organ Sharing, LVEF: left ventricular ejection
fraction, eGFR: estimated glomerular filtration rate, MPAP: mean pulmonary arterial
pressure, PCWP: pulmonary capillary wedge pressure, TPG: transpulmonary gradient,
CO: cardiac output, PVR: pulmonary vascular resistance.
The mean eGFR of the population was 69.9 ± 26.5 ml/min/1.73m2 and RD was
present in 39.4% of recipients. Amongst recipients with RD, the mean eGFR was 44.7 ±
10.9 ml/min/1.73m2. Similar to donors, recipients with RD were older and more likely to
have evidence of CVD in the form of ischemic cardiomyopathy and peripheral vascular
disease. Additionally, recipients with RD exhibited several indices of increased HF-
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disease severity including greater utilization of inotropes and intra-aortic balloon pumps
and higher filling pressures. Pre-transplant allograft function was similar between
recipients with and without RD. When only those recipients who received allografts from
RD-free donors were examined (n=18,919), the observed similarities and differences
between those recipients with and without RD were similar (data not shown).

Recipient RD and timing of graft failure:
Over the entire follow-up period, recipient RD was significantly associated with
poor graft outcomes even following extensive adjustment for donor and recipient
characteristics (Adjusted HR=1.27, 95% CI 1.20-1.34, p<0.001). However, there was a
significant difference in the risk attributable to RD which varied over time (p timedependent interaction = <0.001). Interestingly, the highest risk of graft failure associated
with RD occurred immediately within the first 30 days post-transplant (adjusted HR=1.76,
95% CI 1.54-2.02, p<0.001). The risk associated with RD subsequently decreased as
time went on such that the hazard associated with baseline RD from 30 days to 1 year no
longer significantly impacted subsequent graft survival (HR=0.92, 95% CI 0.77-1.09,
p=0.33, Table 5, Figure 8).
Table 5. Association between recipient renal dysfunction and recipient graft failure
adjusted for donor and recipient risk factors
HR

95% CI

P-value

Recipient Characteristics
eGFR < 60 ml/min/1.73m2, within 1st
month

1.76

1.54-2.02

<0.001
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eGFR < 60 ml/min/1.73m2, 1 month to 1
year
Age, per 10 year increase
Female gender
Gender mismatch
Black race
BMI
Diabetes mellitus
Hypertension*
Cerebrovascular disease
Cigarette use*
Ischemic cardiomyopathy
CMV positive*
Inotrope use
IABP
Mechanical circulatory support
UNOS status 1A
Mechanical ventilation

0.92

0.77-1.09

0.33

0.94

0.92-0.97

<0.007

1.14

1.05-1.24

<0.001

1.17

1.03-1.33

0.015

1.39

1.30-1.49

<0.001

1.00

1.00-1.01

0.23

1.13

1.06-1.21

<0.001

1.14

1.06-1.21

<0.001

1.10

0.98-1.22

0.10

1.06

0.98-1.14

0.16

1.19

1.12-1.26

<0.001

1.03

0.97-1.09

0.30

1.03

0.97-1.09

0.31

1.06

0.94-1.20

<0.31

1.16

1.07-1.27

<0.001

1.12

1.05-1.18

<0.001

1.20

1.03-1.39

0.021

1.06

1.04-1.09

<0.001

1.00

1.00-1.00

0.12

1.11

1.08-1.14

<0.001

Cardiac Allograft Characteristics
Ischemic time, hours
LVEF, %
Donor Characteristics
Age, per 10 year increase
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Female gender
Diabetes mellitus
Hypertension
Cigarette use
CMV positive
Suspected infection (blood)
Cause of death: anoxia
Inotropic support*
eGFR, per 10 ml/min/1.73m2 increase

0.96

0.86-1.07

0.43

1.15

0.97-1.35

0.11

0.96

0.88-1.04

0.31

1.08

1.01-1.14

0.02

1.11

1.05-1.17

<0.001

1.10

1.00-1.22

0.06

1.08

0.99-1.18

0.08

1.04

0.98-1.11

0.23

1.00

1.00-1.01

0.39

*Missing data in these covariates was coded as a separate category due to its prevalence
(9% for donor inotropic support; 50% for recipient hypertension; 36% for recipient
history of cigarette use, 6% for recipient cmv positive status). The associated HR
specifically represents the risk of graft failure in a group with one of these risk factors vs.
without. eGFR: estimated glomerular filtration rate, CMV: cytomegalovirus, LVEF: left
ventricular ejection fraction, RD: renal dysfunction, BMI: body mass Index, IABP: intraaortic balloon pump, UNOS: United Network of Organ Sharing.
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Figure 8. Kaplan-Meier survival curves stratified by recipient eGFR categories. eGFR:
estimated glomerular filtration rate in mL/min/1.73m2.

The attenuation in risk did not appear to be primarily driven by recovery in renal
function; when patients with data on repeat renal function were evaluated (data available
37%, median time to follow-up creatinine = 6.0 years), eGFR in patients with RD did not
meaningfully improve post-transplant (baseline eGFR 45.0 ± 10.5 ml/min/1.73m2 vs.
follow-up eGFR 47.3 ± 20.1 ml/min/1.73m2). Similar findings of an early period of high
risk followed by attenuation in risk was observed when examining only cardiac allografts
from donors without RD (p interaction = 0.13).
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Discussion:
Principal Findings of the Study:
The principal findings of this study are 1) RD in a cardiac donor, regardless of its
severity, is not associated with worsened graft survival and 2) the risk of graft failure
associated with recipient RD is substantial and most pronounced in the first 30 days
following cardiac transplantation with subsequent attenuation in the risk over time. Thus
RD-associated risk cannot be transferred between patients via the myocardium, but
placement of a healthy myocardium into a host with RD results in immediate worsening
in outcomes. The pattern of this risk is most consistent with the concept that the primary
source of risk associated with RD is derived from the peripheral or non-myocardial
aspects of the cardio-renal environment.
A large body of evidence from animal models has clearly demonstrated that
significant adverse myocardial structural changes such as apoptosis, necrosis, and
fibrosis occur with experimentally induced RD.13-20 Given that these are known
mediators of disease in humans, it is reasonable to believe if the above pathology also
occurred in humans with RD it would result in worse outcomes. Importantly, despite
significant pathologic changes, animal systolic function was only mildly or not impaired
at all, suggesting that if this damage occurred in humans it would likely not be avoided
during the allograft screening process.16 Consistent with the above premises, it has
previously been reported that factors which plausibly can cause direct myocardial
damage such as older donor age, hypertension, and diabetes have been linked to
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worsened post-transplant graft survival. These findings serve as “positive controls” that
subclinical myocardial damage in the donor can be transmitted to the recipient despite the
donor screening process.21, 26-30 However, even with severe RD in the donor the risk
associated with donor RD approached zero in a sample size of >23,000 patients.
Although the graft selection process and complicated peri-transplant management of
these patients may have attenuated the signals in this study, the complete lack of a
detectable risk with donor RD argues that the peripheral RD environment is the dominant
factor in RD-associated risk.
Further support for the above concept is provided by the findings with respect to
recipient RD. Importantly, substantial acute systolic dysfunction has not been a
predominant finding in animal models of experimentally induced RD and we could not
detect any signal for worsened outcomes with donor RD, which was likely acute in the
majority of cases.16 As a result even if myocardial damage began to occur immediately
following transplant of a healthy donor heart into a recipient with RD, myocardial
dysfunction would not be expected to manifest itself in immediately worsened outcomes.
Rather, only over months to years as myocardial damage accumulated would we expect
to see worsened outcomes associated with recipient RD if the myocardial pathology was
the dominant driver. To the contrary, we found that when donor hearts were placed into
the environment of recipient RD the opposite pattern was apparent with substantially
increased risk immediately following transplant, followed by attenuation of the risk over
time. Unlike a delayed effect as myocardial injury accumulates from RD, the peripheral
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aspects of RD such as unmeasured disease severity, underutilization of beneficial
therapies (i.e, calcineurin inhibitors), and systemic myocardial depressant factors would
be expected to be the most pronounced immediately after transplant. The finding of a
substantially increased early risk associated with RD followed by subsequent attenuation
is in line with the latter hypothesis.
The direct implication of this study is that transplantation of appropriately
selected hearts from donors with even significant RD does not appear to worsen posttransplant outcomes. However, this analysis also may shed some light on potential
therapeutic approaches toward cardio-renal dysfunction. If transplantation of a heart
from a donor with RD was associated with worse post-transplant outcomes, this would
indicate that once cardio-renal syndrome occurs, the damage is likely irreversible.
However, the absence of a risk associated with donor RD and attenuation of the risk
associated with recipient RD over time post-transplant suggests that the risk associated
with cardio-renal dysfunction may be modifiable. Further research is necessary to better
understand the non-myocardial determinants of RD associated risk and evaluate if
strategies to improve these risk factors could improve outcomes in these patients.

Study Limitations:
This study is subject to limitations inherent to analyses of a retrospective post-hoc
study, such as uncontrolled confounding and reliance on data from a large registry. It is
unclear to what degree transplantation and subsequent treatment with nephrotoxic
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medications such as calcineurin inhibitors may have influenced the RD-graft survival
association. Furthermore, although RD is not a standard parameter that is considered in
the organ selection process, we do not have data on how RD may have affected the organ
refusal rate. Post-transplant decisions such as the choice of immunosuppression may
have been influenced by recipient RD, potentially altering the post-transplant graft failure
risk. Additionally, the graft failure outcome was primarily driven by recipient death,
which could represent non-myocardial events such as infection or malignancy. Although
renal function did not appear to improve post-transplant in the patients with serial
creatinine values available, long-term changes in renal function were not available in the
majority of patients, and when this data was available it was several years after the
transplant. As a result, in some patients improvement in renal function may have
occurred attenuating the risk associated with time of transplant RD at later time periods.
In conclusion, the risk associated with RD does not appear to be transferrable
from donor to recipient via the cardiac allograft and the risk associated with recipient RD
is greatest immediately following transplant. Overall these data support the safety of
transplantation of appropriately selected allografts from donors with RD. Additionally,
these data suggest that the non-myocardial aspects of cardio-renal dysfunction appear to
be of particular importance in driving the risk associated with RD.
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Supplementary materials:
Abstract accepted at Amereican College of Cardiology conference 2014:
Donor and Recipient Renal Dysfunction and Post Cardiac Transplant Graft
Survival - Insights Into Cardiorenal Interactions
Authors: Olga Laur, Meredith Brisco, Alexander Kula, Susan Cheng, Steve Coca, Abeel
Mangi, Wilson Tang, Jeffrey Testani

Background: The major mode of death in patients with renal dysfunction (RD) is
cardiovascular disease (CVD). Notably, there may be a causal effect of RD given that
myocardial necrosis/apoptosis has been seen in animal models of RD. However, RD is
also a marker of overall CVD severity. Cardiac transplantation provides an opportunity to
study this as hearts are being transplanted in and out of the environment of RD: If
irreversible myocardial damage occurs immediately with RD, as seen in animal models
of acute kidney injury, transplantation of a heart from a donor with RD should yield
reduced graft survival. However, if cardiac damage from RD develops gradually,
transplantation of a healthy RD-free donor heart into a recipient with RD should yield an
initial low risk period followed by high event rates months to years later.
Methods: Adult cardiac allograft recipients in the UNOS registry were studied
(n=35,914). RD was defined as estimated glomerular filtration rate (eGFR) < 60
ml/min/1.73m2.
Results: RD was present in 17.2 % of donors and 39.4% of recipients with an overall
worsening in eGFR over time in recipients (p<0.001). Donor characteristics known to
cause or reflect myocardial damage such as ischemic time > 4 hours (adjusted HR 1.2,
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p<0.001), age > 50 years (adjusted HR=1.3, p<0.001), or ejection fraction ≤ 45%
(adjusted HR 1.2, p=0.03) were associated with reduced graft survival. To the contrary,
the risk associated with RD did not follow the heart as transplantation from a donor with
RD did not reduce graft survival (adjusted HR=0.98, p=0.44). RD-free donor hearts
placed into a recipient with RD paradoxically had the highest risk of graft dysfunction in
the first 30 post-operative days (Adjusted HR 1.6, p<0.001). Subsequently, the hazard
attributable to recipient RD (adjusted HR 1.2, p<0.001) did not increase over time
(p=0.8) as would be expected with slow accumulation of myocardial damage from RD.
Conclusion: Transplantation of a heart in and out of the environment of RD was not
associated with worsened outcomes in a manner consistent with a clinically meaningful
direct effect of RD on the myocardium. These data provide additional support that RD
primarily serves as a marker rather than a direct cause of CVD.

Abstract accepted at International Society for Heart and Lung transplantation conference
in April 2014:

Donor and Recipient Renal Dysfunction and Post Cardiac Transplant Graft
Survival - Insights Into Reno-Cardiac Interactions
Authors: Olga Laur, Meredith Brisco, Alexander Kula, Susan Cheng, Steve Coca, Abeel
Mangi, Wilson Tang, Jeffrey Testani

Background: The major mode of death in patients with renal dysfunction (RD) is
cardiovascular disease (CVD). Notably, there may be a causal effect of RD given that
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myocardial necrosis/apoptosis has been seen in animal models of RD. However, RD is
also a marker of overall CVD severity. Cardiac transplantation provides an opportunity to
study this as hearts are being transplanted in and out of the environment of RD: If
irreversible myocardial damage occurs immediately with RD, as seen in animal models
of acute kidney injury, transplantation of a heart from a donor with RD should yield
reduced graft survival. However, if cardiac damage from RD develops gradually,
transplantation of a healthy RD-free donor heart into a recipient with RD should yield an
initial low risk period followed by high event rates months to years later.
Methods: Adult cardiac allograft recipients in the UNOS registry were studied
(n=35,914). RD was defined as estimated glomerular filtration rate (eGFR) < 60
ml/min/1.73m2.
Results: RD was present in 17.2 % of donors and 39.4% of recipients with an overall
worsening in eGFR over time in recipients (p<0.001). Donor characteristics known to
cause or reflect myocardial damage such as ischemic time > 4 hours (adjusted HR 1.2,
p<0.001), age > 50 years (adjusted HR=1.3, p<0.001), or ejection fraction ≤ 45%
(adjusted HR 1.2, p=0.03) were associated with reduced graft survival. To the contrary,
the risk associated with RD did not follow the heart as transplantation from a donor with
RD did not reduce graft survival (adjusted HR=0.98, p=0.44). RD-free donor hearts
placed into a recipient with RD paradoxically had the highest risk of graft dysfunction in
the first 30 post-operative days (Adjusted HR 1.6, p<0.001). Subsequently, the hazard
attributable to recipient RD (adjusted HR 1.2, p<0.001) did not increase over time
(p=0.8) as would be expected with slow accumulation of myocardial damage from RD.
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Conclusion: Transplantation of a heart in and out of the environment of RD was not
associated with worsened outcomes in a manner consistent with a clinically meaningful
direct effect of RD on the myocardium. These data provide additional support that RD
primarily serves as a marker rather than a direct cause of CVD.

